Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17467186 | 0.98 | CYP3A4 (0.55) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL6895750 | 0.95 | CYP3A4 (0.59) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL4630569 | 0.93 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3821063 | 0.87 | CYP3A4 (0.71) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL6868292 | 0.87 | CYP3A4 (0.71) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL536943 | 0.87 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3814693 | 0.87 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL1260434 | 0.87 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL22844591 | 0.87 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL3820824 | 0.87 | CYP3A4 (0.70) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | CYP3A4 16/4885LPAR3 4841/4885LPAR2 4858/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | CYP3A4 16/4885LPAR3 4841/4885LPAR2 4858/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | CYP3A4 978/4885LPAR3 1514/4885LPAR2 3708/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | CYP3A4 733/4885LPAR3 3456/4885LPAR2 4223/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CYP3A4 477/4885LPAR3 403/4885LPAR2 756/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CYP3A4 542/4885LPAR3 1093/4885LPAR2 632/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CYP3A4 22/4885LPAR3 2384/4885LPAR2 2564/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | CYP3A4 733/4885LPAR3 3456/4885LPAR2 4223/4885 |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CYP3A4 257/4885LPAR3 2785/4885LPAR2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.